Table 3.
Cox regression models for outcome hazard ratios by MRSA nasal carriage
| Outcome | MRSA Noncarrier (n = 277)a | MRSA Carrier (n = 29)a | Unadjusted |
Adjustedb |
||
|---|---|---|---|---|---|---|
| HR | Pc | HR | Pc | |||
| Primary outcome | ||||||
| all-cause mortality | 34 (12.27) | 8 (27.59) | 2.45 (1.13–5.3) | 0.02 | 2.46 (1.08–5.62) | 0.03 |
| Secondary outcome | ||||||
| infection-related death | 10 (3.61) | 6 (20.69) | 6.2 (2.25–17.07) | <0.001 | 4.99 (1.52–16.39) | 0.008 |
| hospitalization due to any cause | 104 (37.55) | 13 (44.83) | 1.32 (0.74–2.36) | 0.3 | 1.38 (0.76–2.52) | 0.3 |
| any infection | 60 (21.66) | 10 (34.48) | 1.84 (0.94–3.6) | 0.07 | 2.09 (1.02–4.28) | 0.04 |
| S. aureus infection | 18 (6.5) | 6 (20.69) | 3.69 (1.46–9.29) | 0.01 | 4.31 (1.55–11.97) | 0.01 |
a
The values indicate the number of patients (%).
b
Adjusted for age, gender, diabetes, vascular access type, recent hospitalization, recent antibiotics use, and serum albumin level.
c
The Cox proportional hazards model was used to assess the effect of MRSA nasal carriage on study end points.